# Insomnia and Hypertension: Importance of Objective Phenotyping and Comorbidity with Sleep Apnea

## TL;DR

This paper reviews recent research on how insomnia, especially when combined with sleep apnea, increases the risk of hypertension and highlights the importance of objective sleep measures in diagnosis and treatment.

## Contribution

The paper emphasizes the novel role of insomnia phenotypes and COMISA in hypertension risk and advocates for objective phenotyping in clinical practice.

## Key findings

- Insomnia disorder, especially with short sleep duration, is linked to higher hypertension risk than insomnia symptoms.
- COMISA further increases hypertension risk, though evidence is limited to individual studies.
- Objective sleep measures can serve as biomarkers to guide hypertension treatment decisions.

## Abstract

Provide a synthesis of research from the past five years examining the relationship between insomnia, its phenotypes, and comorbidity with sleep apnea (COMISA), with hypertension. Offer a critical evaluation of current evidence and outline future research directions.

Meta-analytic evidence indicates that the risk of hypertension is higher in patients with insomnia disorder compared to those with insomnia symptoms, with the highest risk observed in the insomnia with objective short sleep duration phenotype. COMISA appears to further amplify this risk, although the evidence is limited to individual studies with no meta-analyses available. There is a clear need for clinical trials to confirm these associations and guide the development of more effective therapeutic strategies.

Insomnia should be part of the diagnostic assessment of patients with hypertension. Objective sleep duration can serve as a biomarker, alongside respiratory indices, to guide therapeutic decision-making and optimize patient management.